| pubmed-article:21734127 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21734127 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:21734127 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:21734127 | lifeskim:mentions | umls-concept:C0004732 | lld:lifeskim |
| pubmed-article:21734127 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21734127 | lifeskim:mentions | umls-concept:C0023290 | lld:lifeskim |
| pubmed-article:21734127 | lifeskim:mentions | umls-concept:C0282462 | lld:lifeskim |
| pubmed-article:21734127 | lifeskim:mentions | umls-concept:C0068006 | lld:lifeskim |
| pubmed-article:21734127 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21734127 | pubmed:dateCreated | 2011-7-7 | lld:pubmed |
| pubmed-article:21734127 | pubmed:abstractText | Miltefosine (target dose of 2.5 mg/kg/day for 28 days) is the recommended treatment for visceral leishmaniasis (kala-azar) in Bangladesh on the basis of data from India. We evaluated miltefosine in a phase IV trial of 977 patients in Bangladesh. At the six-month final follow up, 701 were cured. 24 showed initial treatment failure, and 95 showed treatment failure at 6 months, although 73 of the 95 showed treatment failure solely by the criterion of low hemoglobin values. One hundred twenty-one patients were not assessable. With the conservative assumption that all low hemoglobin values represented treatment failure, the final per protocol cure rate was 85%. Of 13 severe adverse events, 6 led to treatment discontinuation and 7 resulted in deaths, but only 1 death (associated with diarrhea) could be attributed to drug. Nearly all non-serious adverse events were gastrointestinal: vomiting in 25% of patients and diarrhea in 8% of patients. Oral miltefosine is an attractive alternative to intramuscular antimony and intravenous amphotericin B for treatment of kala-azar in Bangladesh. | lld:pubmed |
| pubmed-article:21734127 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21734127 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21734127 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21734127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21734127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21734127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21734127 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21734127 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21734127 | pubmed:issn | 1476-1645 | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:RahmanMahmudu... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:RahmanM... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:BermanJonatha... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:HossainMoazze... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:Mascie-Taylor... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:AranaByronB | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:AhmadZiauddin... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:AhmedBe-Nazir... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:FaizM AbulMA | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:IslamM... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:ChowdhuryM... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:IslamQuazi... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:SayeedurRahma... | lld:pubmed |
| pubmed-article:21734127 | pubmed:author | pubmed-author:BangaliAbdul... | lld:pubmed |
| pubmed-article:21734127 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21734127 | pubmed:volume | 85 | lld:pubmed |
| pubmed-article:21734127 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21734127 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21734127 | pubmed:pagination | 66-9 | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:meshHeading | pubmed-meshheading:21734127... | lld:pubmed |
| pubmed-article:21734127 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21734127 | pubmed:articleTitle | Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. | lld:pubmed |
| pubmed-article:21734127 | pubmed:affiliation | Institute Of Epidemiology, Disease Control and Research, Dhaka, Bangladesh. mrahman@citechco.net | lld:pubmed |
| pubmed-article:21734127 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21734127 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21734127 | pubmed:publicationType | Clinical Trial, Phase IV | lld:pubmed |
